Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is designed as an open-label, dose-escalation manner to determine the MFD of
chidamide in combination with celecoxib in patients with advanced mCRC.